Health-related quality of life is a significant prognostic factor for recurrence and overall survival in patients with colon cancer.

IF 3.4 2区医学 Q2 ONCOLOGY

BMC Cancer Pub Date : 2025-06-10 DOI:10.1186/s12885-025-14254-1

Catarina Tiselius, Fanny Johansen, Andreas Rosenblad, Kenneth Smedh

{"title":"Health-related quality of life is a significant prognostic factor for recurrence and overall survival in patients with colon cancer.","authors":"Catarina Tiselius, Fanny Johansen, Andreas Rosenblad, Kenneth Smedh","doi":"10.1186/s12885-025-14254-1","DOIUrl":null,"url":null,"abstract":"Background: Health-related quality of life (HRQoL) is associated with survival in patients with cancer; however, there are few studies on the risk of cancer recurrence. We investigated whether HRQoL can predict disease-free and overall survival (DFS/OS) in patients with non-metastatic colon cancer.Methods: This population-based prospective study investigated patients diagnosed with colon cancer between 2012 and 2016. The 30-item European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) was used to measure HRQoL at diagnosis. Cox proportional hazard regression analyses were used to analyse the association between QLQ-C30 scores and DFS/OS.Results: Of the 323 patients with non-metastatic colorectal cancer, n = 41 (12.7%) were diagnosed with recurrence during mean (standard deviation) DFS and OS follow-up times of 5.9 (2.9) and 6.2 (2.7) years, respectively. Cox regression analysis of HRQoL, adjusted for important clinical and demographic variables, showed that a higher global health status was significantly associated with an improved DFS (hazard ratio [HR] 0.86 per 10 points; 95% confidence interval [CI] 0.79-0.94; P < 0.001) as well as OS (HR 0.88 per 10 points; 99% CI 0.80-0.96; P = 0.003).Conclusions: These results demonstrate that HRQoL can predict both DFS and OS in patients with non-metastatic colon cancer. HRQoL should be considered an additional tool in non-metastatic cancer for assessing patients at risk of metastatic disease.Trial registration: ClinicalTrials.gov (NCT03910894).","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1016"},"PeriodicalIF":3.4000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150544/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-14254-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Health-related quality of life (HRQoL) is associated with survival in patients with cancer; however, there are few studies on the risk of cancer recurrence. We investigated whether HRQoL can predict disease-free and overall survival (DFS/OS) in patients with non-metastatic colon cancer.

Methods: This population-based prospective study investigated patients diagnosed with colon cancer between 2012 and 2016. The 30-item European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) was used to measure HRQoL at diagnosis. Cox proportional hazard regression analyses were used to analyse the association between QLQ-C30 scores and DFS/OS.

Results: Of the 323 patients with non-metastatic colorectal cancer, n = 41 (12.7%) were diagnosed with recurrence during mean (standard deviation) DFS and OS follow-up times of 5.9 (2.9) and 6.2 (2.7) years, respectively. Cox regression analysis of HRQoL, adjusted for important clinical and demographic variables, showed that a higher global health status was significantly associated with an improved DFS (hazard ratio [HR] 0.86 per 10 points; 95% confidence interval [CI] 0.79-0.94; P < 0.001) as well as OS (HR 0.88 per 10 points; 99% CI 0.80-0.96; P = 0.003).

Conclusions: These results demonstrate that HRQoL can predict both DFS and OS in patients with non-metastatic colon cancer. HRQoL should be considered an additional tool in non-metastatic cancer for assessing patients at risk of metastatic disease.

Trial registration: ClinicalTrials.gov (NCT03910894).

查看原文本刊更多论文

健康相关生活质量是结肠癌患者复发和总生存的重要预后因素。

背景：与健康相关的生活质量（HRQoL）与癌症患者的生存相关；然而，关于癌症复发风险的研究很少。我们研究了HRQoL是否可以预测非转移性结肠癌患者的无病生存和总生存（DFS/OS）。方法：这项基于人群的前瞻性研究调查了2012年至2016年间诊断为结肠癌的患者。采用30项欧洲癌症研究与治疗组织核心生活质量问卷（EORTC QLQ-C30）测量诊断时的HRQoL。采用Cox比例风险回归分析QLQ-C30评分与DFS/OS的相关性。结果：323例非转移性结直肠癌患者中，在平均（标准差）DFS和OS随访时间分别为5.9（2.9）年和6.2（2.7）年期间，n = 41（12.7%）例被诊断为复发。经重要临床和人口学变量调整后的HRQoL的Cox回归分析显示，较高的整体健康状况与改善的DFS显著相关(风险比[HR] 0.86 / 10分；95%置信区间[CI] 0.79-0.94；结论：HRQoL可以预测非转移性结肠癌患者的DFS和OS。HRQoL应被视为非转移性癌症患者评估转移性疾病风险的额外工具。试验注册：ClinicalTrials.gov （NCT03910894）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Cancer 医学-肿瘤学

CiteScore

6.00

自引率

2.60%

发文量

1204

审稿时长

6.8 months

期刊介绍： BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.